Combined Image-guided Radiofrequency and Iodine-125 Seeds Implantation in the Treatment of Recurrent Hepatocellular Carcinoma After Hepatectomy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 May 31

PMID 38822264

Authors

Fei Cao

Jiaping Zheng

Weiyuan Hao

Affiliations

Soon will be listed here.

Abstract

Background: Currently, there is no consensus on the treatment of recurrent hepatocellular carcinoma (HCC) after hepatectomy. It is necessary to assess the efficacy and safety of radiofrequency ablation (RFA) combined with iodine-125 seeds implantation (RFA-I) in the treatment of recurrent HCC.

Methods: This study retrospectively analyzed the clinical data of patients with postoperative recurrence of HCC receiving RFA-I or RFA treatment from January 2013 to January 2023. Both RFA and I seeds implantation were performed under dual guidance of ultrasound and CT. Overall survival (OS), progression-free survival (PFS), recurrence, and complications were compared between the two groups.

Results: A total of 210 patients with recurrent HCC were enrolled in this study, including 125 patients in the RFA-I group and 85 patients in the RFA group. The RFA-I group showed a significantly better survival benefit than RFA group (median OS: 37 months vs. 16 months, P < 0.001; median PFS: 15 months vs. 10 months, P = 0.001). The uni- and multivariate analysis showed that RFA-I was a protective factor for OS and PFS. There were no procedure-related deaths and no grade 3 or higher adverse events in both groups.

Conclusions: RFA combined with I seeds implantation under dual guidance of ultrasound and CT is effective and safe for the treatment of HCC patients with recurrence after hepatectomy.

References

Yan W, Li C, Yao L, Qiu H, Wang M, Xu X . Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study. Hepatobiliary Surg Nutr. 2023; 12(2):155-168. PMC: 10129892. DOI: 10.21037/hbsn-21-288. View

Zhang H, Liu F, Wen N, Li B, Wei Y . Patterns, timing, and predictors of recurrence after laparoscopic liver resection for hepatocellular carcinoma: results from a high-volume HPB center. Surg Endosc. 2021; 36(2):1215-1223. PMC: 8758625. DOI: 10.1007/s00464-021-08390-5. View

Chen K, Chen G, Wang H, Li H, Xiao J, Duan X . Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial. J Hepatol. 2014; 61(6):1304-11. DOI: 10.1016/j.jhep.2014.07.026. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Chen L, Ying X, Zhang D, Lai L, Wu F, Tu J . Iodine-125 Brachytherapy Can Prolong Progression-Free Survival of Patients with Locoregional Recurrence and/or Residual Hepatocellular Carcinoma After Radiofrequency Ablation. Cancer Biother Radiopharm. 2020; 36(10):820-826. DOI: 10.1089/cbr.2020.3647. View

Jeon M, Kim H, Lim T, Han D, Kim B, Park J . Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. PLoS One. 2019; 14(4):e0214613. PMC: 6449032. DOI: 10.1371/journal.pone.0214613. View

Bai X, Cui M, Yang W, Wang H, Wang S, Zhang Z . The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC. Radiology. 2021; 300(2):458-469. DOI: 10.1148/radiol.2021200153. View

Kunzli B, Abitabile P, Maurer C . Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future. World J Hepatol. 2011; 3(1):8-14. PMC: 3035700. DOI: 10.4254/wjh.v3.i1.8. View

Chen Z, Fu X, Qiu Z, Mu M, Jiang W, Wang G . CT-guided I brachytherapy for hepatocellular carcinoma in high-risk locations after transarterial chemoembolization combined with microwave ablation: a propensity score-matched study. Radiol Oncol. 2023; 57(1):127-139. PMC: 10039481. DOI: 10.2478/raon-2023-0012. View

10.

Ren Y, Dong X, Chen L, Sun T, Alwalid O, Kan X . Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization. Front Oncol. 2021; 11:582544. PMC: 7961082. DOI: 10.3389/fonc.2021.582544. View

11.

Grieco C, Simon C, Mayo-Smith W, DiPetrillo T, Ready N, Dupuy D . Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer. J Vasc Interv Radiol. 2006; 17(7):1117-24. DOI: 10.1097/01.RVI.0000228373.58498.6E. View

12.

Lucchina N, Tsetis D, Ierardi A, Giorlando F, Macchi E, Kehagias E . Current role of microwave ablation in the treatment of small hepatocellular carcinomas. Ann Gastroenterol. 2016; 29(4):460-465. PMC: 5049552. DOI: 10.20524/aog.2016.0066. View

13.

McGlynn K, Petrick J, El-Serag H . Epidemiology of Hepatocellular Carcinoma. Hepatology. 2020; 73 Suppl 1:4-13. PMC: 7577946. DOI: 10.1002/hep.31288. View

14.

Lee D, Lee M, Kim P, Lee Y, Park H, Lee J . Outcome of No-Touch Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Multicenter Clinical Trial. Radiology. 2021; 301(1):229-236. DOI: 10.1148/radiol.2021210309. View

15.

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

16.

Zhang Y, Wu Y, Yue Z, Zhao H, Wang L, Fan Z . Iodine-125 implantation with transjugular intrahepatic portosystemic shunt for main portal vein tumor thrombus. World J Gastrointest Oncol. 2019; 11(4):310-321. PMC: 6475673. DOI: 10.4251/wjgo.v11.i4.310. View

17.

McWilliams J, Yamamoto S, Raman S, Loh C, Lee E, Liu D . Percutaneous ablation of hepatocellular carcinoma: current status. J Vasc Interv Radiol. 2010; 21(8 Suppl):S204-13. DOI: 10.1016/j.jvir.2009.11.025. View

18.

Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P . Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. Oncologist. 2019; 24(10):e990-e1005. PMC: 6795153. DOI: 10.1634/theoncologist.2018-0337. View

19.

Koh P, Chan A, Cheung T, Chok K, Dai W, Poon R . Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxford). 2016; 18(1):72-8. PMC: 4750229. DOI: 10.1016/j.hpb.2015.07.005. View

20.

Wang Q, Tang M, Zhang S . Comparison of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: a meta-analysis. ANZ J Surg. 2021; 91(7-8):E432-E438. DOI: 10.1111/ans.16560. View